Research location
North Ryde
New South Wales, Australia
Advertisement
Research activity in North Ryde
New South Wales, AustraliaCureCurrent currently publishes aggregate city-level research activity for this location: 24 trials and 26 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in North Ryde
24 linked trials · page 1 of 1This is a Study to Learn About How the Combination of the Study Medicines Sigvotatug Vedotin Plus Pembrolizumab Works in People With Non-small Cell Lung Cancer With High Levels of PD-L1.NCT06758401 · 2025-07-23 · 1 site observation
RECRUITING
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)NCT06966700 · 2025-06-30 · 1 site observation
RECRUITING
A Study of DM005 in Patients With Advanced Solid TumorsNCT06515990 · 2024-10-31 · 1 site observation
RECRUITING
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid TumorsNCT06120283 · 2023-12-01 · 1 site observation
RECRUITING
Phase 3 Study of Xaluritamig vs Cabazitaxel or Second Androgen Receptor-Directed Therapy in Participants With Progressive Metastatic Castration-Resistant Prostate Cancer (XALute)NCT06691984 · 2024-12-09 · 1 site observation
ACTIVE_NOT_RECRUITING
Study of SPG302 in Healthy Volunteers and ALS ParticipantsNCT05882695 · 2023-07-03 · 1 site observation
COMPLETED
NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid TumorsNCT05252390 · 2022-03-29 · 1 site observation
TERMINATED
Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsNCT04084678 · 2021-01-20 · 1 site observation
TERMINATED
Study of First-line Pembrolizumab (MK-3475) With Lenvatinib (MK-7902/E7080) in Urothelial Carcinoma Cisplatin-ineligible Participants Whose Tumors Express Programmed Cell Death-Ligand 1 and in Participants Ineligible for Platinum-containing Chemotherapy (MK-7902-011/E7080-G000-317/ LEAP-011)NCT03898180 · 2019-05-06 · 1 site observation
COMPLETED
A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast CancerNCT03701334 · 2018-12-07 · 1 site observation
ACTIVE_NOT_RECRUITING
Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)NCT03358472 · 2017-12-01 · 1 site observation
COMPLETED
Javelin Parp Medley: Avelumab Plus Talazoparib In Locally Advanced Or Metastatic Solid TumorsNCT03330405 · 2017-10-19 · 1 site observation
TERMINATED
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid TumorsNCT03170960 · 2017-09-05 · 1 site observation
ACTIVE_NOT_RECRUITING
Effect of Enzalutamide Dose Reduction on Fatigue, Cognition, and Drug Trough Levels in Patients With Prostate CancerNCT03124615 · 2017-05-01 · 1 site observation
UNKNOWN
221AD301 Phase 3 Study of Aducanumab (BIIB037) in Early Alzheimer's DiseaseNCT02477800 · 2015-08-13 · 1 site observation
TERMINATED
AD-4833/TOMM40_303 Extension Study of the Safety and Efficacy of Pioglitazone to Slow Cognitive Decline in Participants With Mild Cognitive Impairment Due to Alzheimer DiseaseNCT02284906 · 2015-02-12 · 1 site observation
TERMINATED
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBARK)NCT02319837 · 2014-12-17 · 1 site observation
ACTIVE_NOT_RECRUITING
Bronchial Thermoplasty Global RegistryNCT02104856 · 2014-01-01 · 1 site observation
COMPLETED
Safety and Efficacy Study of Enzalutamide in Patients With Nonmetastatic Castration-Resistant Prostate CancerNCT02003924 · 2013-10-31 · 2 site observations
COMPLETED
Safety Study of Continued Enzalutamide Treatment In Prostate Cancer PatientsNCT01995513 · 2013-10-22 · 2 site observations
COMPLETED
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its OnsetNCT01931566 · 2013-08-01 · 1 site observation
TERMINATED
MitraClip System in Australia and New ZealandNCT01301625 · 2011-11-01 · 1 site observation
TERMINATED
LUX Lung Special Access Scheme Australia Named Patient Use (NPU)NCT01209650 · 1 site observation
APPROVED_FOR_MARKETING
Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)NCT02389933 · 1 site observation
NO_LONGER_AVAILABLE
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.